2-benzyl-3-(4-methoxybenzoyl)propionic acid | 89496-35-5

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 英文名称: 2-benzyl-3-(4-methoxybenzoyl)propionic acid
• 英文别名: 2-benzyl-4-(4-methoxyphenyl)-4-oxo-butyric acid；3-p-Methoxybenzoyl-2-benzylpropionsaeure；2-Benzyl-4-(4-methoxy-phenyl)-4-oxo-buttersaeure；2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid；2-Benzyl-3-(4-methoxybenzoyl)propanoic acid
• CAS: 89496-35-5
• 化学式: C₁₈H₁₈O₄
• 分子量: 298.339
• InChiKey: TVLYZHRGSUXOQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-benzyl-3-(4-methoxybenzoyl)propionic acid 在 盐酸 、 amalgamated zinc 、 三氯化磷 作用下， 生成 2-Benzyl-7-methoxy-3,4-dihydro-2H-naphthalen-1-one
  参考文献：
  名称：

  Genetic variability and expression of phenological and morphological differences in populations of Delia radicum (Diptera: Anthomyiidae)

  摘要：

  摘要 本研究测定了林尼厄斯蝇（Delia radicum Linneaus）早龄和晚龄表型的成虫存活率、未成熟期发育持续时间、卵微形态、DNA多态性和生殖相容性，以确定这两种表型是否存在除蛹发育持续时间以外的进化差异，并找到控制这两种表型表达的最可能的遗传系统。早发和晚发表型在成虫阶段的存活率没有显著差异。测试的随机扩增多态性 DNA（RAPD）引物表明，可以区分早出蝇和晚出蝇。此外，研究结果表明，早发和晚发表型不仅在成虫出现的时间上不同，而且在卵的结构（卵微形态）以及幼虫和蛹的死亡率上也不同。这两种表型在生殖或生态上并不隔离。控制滇金丝猴种群中早期和晚期成虫表达的遗传系统可能是一种适应性策略，可减少捕食者和寄生虫的压力，优化资源利用，确保滇金丝猴在非典型冬季存活。如果负责寄主植物选择和在新寄主上的适应性的几个关键基因座发生变化，这种策略最终可能会导致时间上的同域物种分化。

  DOI：

  10.4039/ent134311-3
• 作为产物：
  描述：

  2-(4-methoxy-phenacyl)-3-phenyl-acrylic acid 在 palladium on activated charcoal 、 乙酸乙酯 作用下， 生成 2-benzyl-3-(4-methoxybenzoyl)propionic acid
  参考文献：
  名称：

  Borsche; Hofmann; Kuehn, Justus Liebigs Annalen der Chemie, 554 <1943< 23, 33

  摘要：

  DOI：

文献信息

• [EN] ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE ALPHA-AMINO BORONIQUE, INHIBITEURS SÉLECTIFS DE L'IMMUNOPROTÉASOME
  申请人：ARES TRADING SA

  公开号：WO2013092979A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.

  本发明提供了化合物的公式（I）作为LMP7的抑制剂，用于治疗自身免疫和炎症性疾病。在公式（I）中，Rb和Rc分别独立地从H或C1-C6-烷基中选择；其中Rb和Rc可以连接形成一个含有它们连接的氧原子的5或6元环；Q表示Ar，Het或环烷基；R1和R2彼此独立地表示H，ORa，Hal，C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Y表示CR 3R4，优选CH2或C(CH3)2；R3，R4彼此独立地表示H或C1-C6-烷基；L表示L1或L2或烷基；n是从0到3选择的整数；L1是Q1-CO-M-，其中Q1是Ar或Het，优选苯基，萘基或吡啶基，可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；L2是Q2-M-，其中Q2是含有1个氮原子和1到3个额外基团的融合双环系统，独立选择自O，S，N或CO，其中至少一个环是芳香环，融合双环系统可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；或Q2是不饱和或芳香的含有1到3个从N，O，S和CO中选择的杂原子的5元环系统，并可选地取代为苯环或吡啶环，其中苯环和吡啶环可选地取代为1到4个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；M是具有1到5个碳原子的线性或支链烷基，其中1或2个H原子可以被ORa或可选地取代为1到5个从Hal，ORa和C1-C6-烷基中独立选择的基团，可选地取代为1到5个从OH和Hal中独立选择的基团；或M表示具有3到7个碳原子的环烷基；或M表示噻唑烷基；Ra是H或C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Ar表示一个6元芳香碳环，可选地与另一个含有5到8个碳原子的碳环饱和、不饱和或芳香环融合；Het表示一个含有1到3个从N，N+O-，O，S，SO和SO2中独立选择的杂原子的5或6元饱和、不饱和或芳香杂环，可选地与另一个含有5到8个原子的饱和、不饱和或芳香环融合，并可选地含有1到3个从N，O和S中选择的杂原子；Hal表示CI，Br，I或F；优选CI或F。
• [EN] KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS DE LA KYNURENINE 3-HYDROXYLASE POUR LE TRAITEMENT DU DIABETE
  申请人：MERCK PATENT GMBH

  公开号：WO2004060369A1

  公开（公告）日：2004-07-22

  The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes.

  本发明涉及使用至少一种对酮烟酸3-羟化酶具有抑制活性的化合物制备用于预防和/或治疗糖尿病的药物。
• Pharmaceutical composition containing 4-oxo-butynic acids
  申请人：Merck Patent Gesellschaft Mit

  公开号：US06143787A1

  公开（公告）日：2000-11-07

  The present invention relates to a pharmaceutical composition comprising, as active principle, a compound of formula: ##STR1## in which the groups A and B are chosen, independently of each other, from: a mono-, bi- or tricyclic aryl group having from 6 to 14 carbon atoms; a heteroaromatic group chosen from pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups; an alkyl group having from 1 to 14 carbon atoms; a cycloalkyl group having from 5 to 8 carbon atoms; a saturated heterocyclic group chosen from tetrahydrofuryl, tetrahydropyranyl, piperidyl and pyrrolidinyl groups; to its solvate or to a salt of this acid with a pharmaceutically acceptable base. Figures: none.

  本发明涉及一种制药组合物，其作为活性原理包含以下化合物：##STR1## 其中，A和B组分别独立地选择自：具有6至14个碳原子的单环、双环或三环芳基基团；从吡啶基、嘧啶基、吡咯基、呋喃基和噻吩基中选择的杂环芳基基团；具有1至14个碳原子的烷基基团；具有5至8个碳原子的环烷基基团；从四氢呋喃基、四氢吡喃基、哌啶基和吡咯烷基中选择的饱和杂环基团；以及其溶剂化物或与药用可接受碱的盐。图形：无。
• Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
  申请人：Ares Trading S.A.

  公开号：US20140364396A1

  公开（公告）日：2014-12-11

  The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases.

  本发明提供了化合物(I)的公式，作为LMP7的抑制剂，用于治疗自身免疫和炎症性疾病。
• Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
  申请人：Moinet Gerard

  公开号：US20050014768A1

  公开（公告）日：2005-01-20

  The present invention relates to the use of a 4-oxobutanoic acid derivative for the preparation of a pharmaceutical composition for treating inflammation.

  本发明涉及使用 4-氧代丁酸衍生物制备治疗炎症的药物组合物。